Alamar Capital Management LLC Has $2.87 Million Stock Position in DexCom, Inc. $DXCM

Alamar Capital Management LLC lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 1.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 32,868 shares of the medical device company’s stock after selling 652 shares during the period. DexCom makes up about 1.6% of Alamar Capital Management LLC’s holdings, making the stock its 29th largest position. Alamar Capital Management LLC’s holdings in DexCom were worth $2,869,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Brighton Jones LLC grew its stake in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the period. Oppenheimer & Co. Inc. grew its stake in DexCom by 4.8% in the first quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical device company’s stock valued at $1,449,000 after acquiring an additional 974 shares during the period. Asset Management One Co. Ltd. grew its stake in DexCom by 4.1% in the first quarter. Asset Management One Co. Ltd. now owns 253,355 shares of the medical device company’s stock valued at $17,302,000 after acquiring an additional 9,980 shares during the period. Bessemer Group Inc. grew its stake in DexCom by 2.8% in the first quarter. Bessemer Group Inc. now owns 949,091 shares of the medical device company’s stock valued at $64,812,000 after acquiring an additional 25,459 shares during the period. Finally, Golden State Wealth Management LLC grew its stake in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 264 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of research reports. Barclays raised their price objective on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Argus initiated coverage on DexCom in a research note on Thursday, August 21st. They issued a “buy” rating and a $100.00 price objective for the company. The Goldman Sachs Group dropped their target price on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Truist Financial dropped their target price on DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Finally, Oppenheimer lowered DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $96.40.

Insiders Place Their Bets

In related news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is owned by insiders.

DexCom Stock Up 0.5%

DXCM stock opened at $71.06 on Friday. The stock’s 50 day moving average is $72.59 and its 200-day moving average is $77.71. The firm has a market capitalization of $27.87 billion, a PE ratio of 49.35, a P/E/G ratio of 1.49 and a beta of 1.47. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.